Lv414
433 积分 2022-03-03 加入
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
1天前
已完结
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
4天前
求助中
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
4天前
已关闭
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
5天前
已关闭
Head and Neck Cancer A Review
11天前
已关闭
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
16天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
16天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
23天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
23天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
1个月前
已完结
皖公网安备34019202002308
